Free exam prep

BCSCP Board Certified Sterile Compounding Pharmacist

6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>)

Q: A compounding pharmacist prepares a continuous intrathecal infusion of clonidine hydrochloride (500\,\mu\text{g/mL}) with a maximum prescribed hourly dose of 21\,\mu\text{g/hr} in a 70\,\text{kg} adult. Using the compendial endotoxin formula (EL = K/M) under USP , what is the calculated bacterial endotoxin limit per microgram of clonidine?

0.67\,\text{EU/}\mu\text{g}. For intrathecal administration, the threshold pyrogenic dose K is 0.2\,\text{EU/kg}. The hourly dose per kg is M = 21\,\mu\text{g} / 70\,\text{kg} = 0.3\,\mu\text{g/kg/hr}. Calculating the endotoxin limit: EL = K / M = 0.2\,\text{EU/kg} / 0.3\,\mu\text{g/kg} = 0.67\,\text{EU/}\mu\text{g}. The lower K value of 0.2\,\text{EU/kg} is mandatory because cerebrospinal fluid lacks systemic dilution and is 25 times more sensitive to pyrogenic shock than peripheral tissue.

Q: When performing compendial sterility testing per USP on a batch of compounded sterile preparations, what are the mandatory growth media, incubation temperatures, and minimum incubation duration required to confirm product sterility?

Fluid Thioglycollate Medium at 32.5^\circ\text{C} \pm 2.5^\circ\text{C} and Soybean-Casein Digest Medium at 22.5^\circ\text{C} \pm 2.5^\circ\text{C} for a minimum of 14 continuous days. USP mandates the simultaneous incubation of two media for at least 14 continuous days: Fluid Thioglycollate Medium (FTM) incubated at 32.5^\circ\text{C} \pm 2.5^\circ\text{C} (targeting obligate anaerobes, facultative anaerobes, and mesophilic bacteria) and Soybean-Casein Digest Medium (TSB) incubated at 22.5^\circ\text{C} \pm 2.5^\circ\text{C} (targeting fungi, yeasts, molds, and aerobic bacteria). A test can be declared sterile only after the full 14 days have elapsed without turbidity.

Key Takeaways

Sterility testing per USP <71> requires membrane filtration (preferred) or direct inoculation into two media: Fluid Thioglycollate Medium (FTM, 32.5°C) and Soybean-Casein Digest Medium (TSB, 22.5°C) for a mandatory 14-day incubation period.
Method suitability testing (Bacteriostasis/Fungistasis testing) is required prior to relying on USP <71> to confirm that the drug substance does not inhibit microbial growth in the test media.
Bacterial Endotoxin Testing (BET) per USP <85> utilizes Limulus Amebocyte Lysate (LAL) to quantify endotoxins; the endotoxin limit is calculated as $K / M$ , where $K = 5.0\,\text{EU/kg}$ for general parenterals and $K = 0.2\,\text{EU/kg}$ for intrathecal medications.
USP <788> sets subvisible particulate limits: small-volume parenterals ( $\le 100\,\text{mL}$ ) cannot exceed 6,000 particles $\ge 10\,\mu\text{m}$ or 600 particles $\ge 25\,\mu\text{m}$ per container.

Last updated: September 2026

The Three Pillars of Release Testing

Release testing confirms that a compounded sterile preparation meets its specifications before patients receive it. Under USP <797> Section 12, every CSP is visually inspected, and sterility and endotoxin testing are required when the category and BUD call for them. The three laboratory standards that matter most are:

Sterility Testing (USP <71>): Confirms absence of viable bacteria and fungi.
Bacterial Endotoxin Testing (USP <85>): Quantifies pyrogenic lipopolysaccharides.
Particulate Matter Testing (USP <788>): Sets subvisible particle limits for injections. Compounders use it as a quality benchmark, but USP <797> does not list it as a CSP release test.

When USP <797> Requires Sterility and Endotoxin Testing

Situation	Sterility test	Bacterial endotoxin test
Category 1	Not required	Not required
Category 2, Table 13 BUD without testing	Not required	Should be done for injectables made from nonsterile components
Category 2 with a BUD that requires sterility testing	Required	Required for injectables made from nonsterile components
Category 3	Required for every batch	Required for injectables made from nonsterile components

Batch size: any batch that requires sterility testing is capped at 250 final yield units.
Small batches: if 1 to 39 CSPs are made, extra units equal to 10% of the batch, rounded up, are made for testing (1 CSP needs 1 extra; 39 CSPs need 4 extra). For 40 or more, the sample sizes in USP <71> Table 3 apply.
Methods: USP <71> with its Method Suitability Test, or an alternative validated per USP <1223> that is non-inferior to <71>.
Failures: a failed sterility test starts an investigation that includes identifying the organism and reviewing the test, the facility, the process and the personnel, then deciding whether other CSPs are affected. The investigation and corrective actions must be documented.
Dispensing before results: allowed only with procedures in place to notify the prescriber immediately of a failure, recall unused CSPs, quarantine stock, and check other lots (USP <797> 18.1).

Sterility Testing per USP General Chapter <71>

Testing Methods

Membrane Filtration (Preferred Method): The drug solution is passed through two $0.45\,\mu\text{m}$ analytical membrane filter canisters. The filters are rinsed with sterile diluent (Fluid A or D) to wash away antimicrobial drug residues, and media is introduced directly into the closed canisters.
Direct Inoculation: Used only when the drug solution cannot be filtered (e.g., oily suspensions, emulsions). An aliquot of the drug is injected directly into growth media.

Dual Growth Media & Incubation Conditions

Growth Medium	Incubation Temperature	Target Organisms	Mandatory Incubation Duration
Fluid Thioglycollate Medium (FTM)	$32.5^\circ\text{C} \pm 2.5^\circ\text{C}$	Obligate and facultative anaerobes; mesophilic aerobes	14 days
Soybean-Casein Digest Medium (TSB)	$22.5^\circ\text{C} \pm 2.5^\circ\text{C}$	Fungi (yeasts and molds); aerobic bacteria	14 days

Important

A passing sterility test can be declared only after the full 14-day incubation. If turbidity or growth appears in either medium during the 14 days, the test fails, unless the laboratory proves the test itself was invalid. The batch is rejected or recalled, and an investigation follows.

Method Suitability (Bacteriostasis and Fungistasis / B&F Testing)

Before a laboratory can perform USP <71> testing on a specific drug formulation, it must conduct Method Suitability Testing. B&F testing inoculates test media containing the drug with low levels ( $< 100\,\text{CFU}$ ) of six compendial challenge organisms (S. aureus, P. aeruginosa, B. subtilis, C. albicans, A. brasiliensis, C. sporogenes). If the drug inhibits growth, neutralizing agents or enhanced wash volumes must be validated to prevent false-negative sterility tests.

Bacterial Endotoxin Testing (BET) per USP General Chapter <85>

Bacterial endotoxins are heat-stable lipopolysaccharides derived from the outer cell membrane of Gram-negative bacteria. When introduced intravenously or intrathecally, endotoxins bind to macrophage CD14/TLR4 receptors, triggering massive cytokine cascades (fever, septic shock, disseminated intravascular coagulation, death).

The Limulus Amebocyte Lysate (LAL) Reagent

BET utilizes an aqueous extract of circulating blood cells (amebocytes) from the horseshoe crab (Limulus polyphemus). When endotoxin encounters LAL enzymes, an enzymatic clotting cascade is initiated:

Gel Clot Assay: Qualitative clotting endpoint (formation of a firm, inverted gel).
Chromogenic Assay: Colorimetric cleavage of a synthetic peptide releasing yellow $p$ -nitroaniline.
Turbidimetric Assay: Spectrophotometric measurement of optical turbidity as clotting progresses.

The Compendial Endotoxin Limit Formula

The maximum allowable endotoxin limit ( $EL$ ) for any parenteral drug is calculated as:

$EL = \frac{K}{M}$

Where:

$K$ = The threshold pyrogenic human dose of endotoxin per kilogram of body weight:
- $K = 5.0\,\text{EU/kg}$ for any parenteral route other than intrathecal.
- $K = 0.2\,\text{EU/kg}$ for the intrathecal route (because cerebrospinal fluid is 25 times more sensitive to pyrogenic shock!).
$M$ = The maximum recommended human dose of the drug administered per kilogram of body weight within a single 1-hour period (if weight-based dosing is unknown, assume an average adult weight of $70\,\text{kg}$ ).

Worked Clinical Example: A patient receives intravenous vancomycin at a maximum dose of $15\,\text{mg/kg/hr}$ . What is the endotoxin limit?

$EL = \frac{5.0\,\text{EU/kg}}{15\,\text{mg/kg}} = 0.33\,\text{EU/mg}$

Particulate Matter in Injections (USP General Chapter <788>)

Insoluble subvisible particles (silicone droplets, rubber fragments, glass lamellae, cellulose fibers) can cause pulmonary microvascular occlusion and granuloma formation. USP <788> specifies limits using Light Obscuration (LO) particle counters:

Preparation Volume	Maximum Particles $\ge 10\,\mu\text{m}$	Maximum Particles $\ge 25\,\mu\text{m}$
Small-Volume Parenterals (SVP, $\le 100\,\text{mL}$ )	$\le 6,000$ per container	$\le 600$ per container
Large-Volume Parenterals (LVP, $> 100\,\text{mL}$ )	$\le 25$ particles per mL	$\le 3$ particles per mL

Method Suitability Testing: Overcoming False Negatives in Sterility Testing

Compendial sterility testing is susceptible to false-negative results if the compounded formulation possesses intrinsic antimicrobial or antifungal properties. Under USP <71>, Method Suitability Testing (formerly Bacteriostasis and Fungistasis / B&F testing) must be documented prior to releasing patient batches:

Experimental Design of Method Suitability

Challenge Inoculation: Test aliquots of the drug formulation are inoculated with low inocula (less than 100 CFU) of six reference challenge microorganisms:
- Staphylococcus aureus (Gram-positive aerobe)
- Pseudomonas aeruginosa (Gram-negative aerobe)
- Bacillus subtilis (spore-forming aerobe)
- Clostridium sporogenes (obligate spore-forming anaerobe)
- Candida albicans (yeast)
- Aspergillus brasiliensis (filamentous mold)
Growth Promotion Verification: Parallel control containers containing growth media without drug are simultaneously inoculated with identical challenge organisms.
Acceptance Criteria: Conspicuous growth of all challenge organisms must occur within 3 to 5 days in the presence of the drug, matching control growth rates.

Neutralization and Wash Strategies

When an antibiotic, preservative, or antifungal inhibits microbial replication in test canisters, analysts must validate neutralization strategies:

Membrane Rinsing (Fluid A / Fluid D): Increasing wash volumes across 0.45-micron filters up to 500 mL per canister to desorb residual drug.
Chemical Inactivation: Adding compendial beta-lactamases (penicillinase) to hydrolyze beta-lactam antibiotics, or polysorbate 80 / lecithin to neutralize phenolic or quaternary ammonium preservatives.

Test Your Knowledge

A compounding pharmacist prepares a continuous intrathecal infusion of clonidine hydrochloride ( $500\,\mu\text{g/mL}$ ) with a maximum prescribed hourly dose of $21\,\mu\text{g/hr}$ in a $70\,\text{kg}$ adult. Using the compendial endotoxin formula ( $EL = K/M$ ) under USP <85>, what is the calculated bacterial endotoxin limit per microgram of clonidine?

$2.50\,\text{EU/}\mu\text{g}$

$0.20\,\text{EU/}\mu\text{g}$

$0.05\,\text{EU/}\mu\text{g}$

$0.67\,\text{EU/}\mu\text{g}$

Test Your Knowledge

When performing compendial sterility testing per USP <71> on a batch of compounded sterile preparations, what are the mandatory growth media, incubation temperatures, and minimum incubation duration required to confirm product sterility?

Fluid Thioglycollate Medium at $32.5^\circ\text{C} \pm 2.5^\circ\text{C}$ and Soybean-Casein Digest Medium at $22.5^\circ\text{C} \pm 2.5^\circ\text{C}$ for a minimum of 14 continuous days

Nutrient Agar at $37^\circ\text{C}$ and Sabouraud Dextrose Agar at $25^\circ\text{C}$ for a minimum of 48 hours

Tryptic Soy Broth at $35^\circ\text{C}$ for 7 days followed by subculture on blood agar for 3 days

Fluid Thioglycollate Medium at $22.5^\circ\text{C} \pm 2.5^\circ\text{C}$ and Brain Heart Infusion Broth at $42^\circ\text{C}$ for 5 continuous days

Test Your Knowledge

A quality control analyst evaluates a $50\,\text{mL}$ vial of compounded sterile ropivacaine injection using Light Obscuration per USP <788>. Particle analysis reveals an average count of 4,200 particles $\ge 10\,\mu\text{m}$ and 380 particles $\ge 25\,\mu\text{m}$ in the container. How should the analyst interpret these results relative to the compendial small-volume parenteral (SVP) thresholds?

The batch fails because total particles $\ge 10\,\mu\text{m}$ exceed the limit of 25 particles per mL

The batch passes because particle counts comply with the limits of $\le 6{,}000$ particles $\ge 10\,\mu\text{m}$ and $\le 600$ particles $\ge 25\,\mu\text{m}$ per container

The batch fails because particles $\ge 25\,\mu\text{m}$ exceed the maximum ceiling of 3 particles per mL

The batch is inconclusive and must immediately undergo destructive microscopic membrane examination

Sections you finish are checked off in the contents.

Up Next

6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection

Continue learning